Abstract
Introduction
The obesity market is easily characterized as attractive, featuring a booming
patient potential needing long term therapy, but repeated product withdrawals
and failed pipeline candidates highlight the reality of increasingly cautious
regulatory bodies, reluctant payers, and a clinical community that puts more
stock in diet and exercise: $513.7m sales in 2008 fall far short of analyst
predictions.
Key reasons to purchase this research
- Understand why predictions for this market have been repeatedly over-stated
- Qualify market expectations against the practicalities of targeting this
unyielding market
- Assess the qualities of marketed and pipeline products and their
commercial handling to determine their realistic prospects
Table of Contents
OVERVIEW
- This product contains forecasts for obesity drugs across the seven major
markets from 2009 to 2018. It has been designed for delivery in an excel data
pack format.
- The associated report and PowerPoint presentation can be found under
Latest research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
